Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411353 | 0.89 | CCR4 (0.34) | DGAT1 | |
| SCHEMBL31411302 | 0.86 | DGAT1 (0.36) | DGAT1F2RL1NPC1 | |
| SCHEMBL31411410 | 0.85 | NPC1 (0.34) | DGAT1F2RL1NPC1ALOX5APFEN1 | |
| SCHEMBL31411265 | 0.83 | DGAT1 (0.36) | DGAT1F2RL1 | |
| SCHEMBL31411386 | 0.81 | DGAT1 (0.38) | DGAT1F2RL1NPC1 | |
| SCHEMBL31411336 | 0.81 | CCR4 (0.35) | DGAT1F2RL1 | |
| SCHEMBL31411387 | 0.79 | DGAT1 (0.34) | DGAT1F2RL1 | |
| SCHEMBL31411279 | 0.79 | EGFR (0.33) | DGAT1 | |
| SCHEMBL31411481 | 0.79 | EGFR (0.31) | DGAT1F2RL1 | |
| SCHEMBL31411296 | 0.77 | F2RL1 (0.35) | DGAT1F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | DGAT1 1102/4885F2RL1 4296/4885NPC1 539/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | DGAT1 1102/4885F2RL1 4296/4885NPC1 539/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | DGAT1 1102/4885F2RL1 4296/4885NPC1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.